Internationalized domain name

Azra AI Appoints John Marshall as New CEO

Retrieved on: 
onsdag, maj 8, 2024
Data Management, Technology, Managed Care, Other Health, Health, Oncology, Health Technology, Software, Artificial Intelligence, Hospitals, Internet, Cancer, ROI, Azra, Hospital, Pathology, Artificial intelligence, Software as a service, History, IPO, Radiology, Medical Education Number, Patient, Acquisition, Data management, Multimedia, Internationalized domain name

Azra AI , a healthtech leader harnessing artificial intelligence (AI) and workflow automation to accelerate the identification and treatment of cancer, is thrilled to announce the appointment of John Marshall as its new Chief Executive Officer.

Key Points: 
  • Azra AI , a healthtech leader harnessing artificial intelligence (AI) and workflow automation to accelerate the identification and treatment of cancer, is thrilled to announce the appointment of John Marshall as its new Chief Executive Officer.
  • Marshall will succeed Chris Cashwell, who will continue to support Azra as an advisor.
  • "Given the increasing demand for AI-driven healthcare solutions, John Marshall is the ideal leader to propel Azra AI to new heights.
  • With John Marshall's strategic leadership and focus on expanding the platform's innovative capabilities, Azra AI will continue to drive impactful improvements in operational efficiency, patient care, and service line growth across the healthcare industry.

VBI Vaccines Reports Full Year 2023 Financial Results

Retrieved on: 
tisdag, april 16, 2024
Research, Infectious Diseases, FDA, Clinical Trials, Other Health, Biotechnology, Pharmaceutical, Health, Science, Oncology, Shekel, Sale, Net, GAAP, MLE, Walmart, Pharmacy, Green Book, Government, Hepatitis B vaccine, Green, Prison, Research and development, Partnership, Control arm, GBM, Vaccine, Administration, Disease, Exercise, Patient, Carmustine, CAD, VBI, Hepatitis B, Messenger, Bank statement, Israeli new shekel, Internationalized domain name, Growth, Pharmaceutical industry

VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today provided a business update and announced financial results for the year ended December 31, 2023.

Key Points: 
  • VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today provided a business update and announced financial results for the year ended December 31, 2023.
  • Revenues, net: Revenues, net for the full year 2023 were $8.7 million as compared to $1.1 million for the same period in 2022.
  • Cost of Revenues: Cost of revenues was $12.5 million for the full year 2023 as compared to $11.3 million in 2022.
  • Non-GAAP financial measures are meant to supplement, and to be viewed in conjunction with, GAAP financial results.

OMNY Health launches new GI real-world data solutions in partnership with leading US gastroenterology practices

Retrieved on: 
måndag, april 22, 2024
Ulcerative colitis, Gastroenterology, Crohn's disease, Ophthalmology, Health, OMNY, Electronic health record, Partnership, Research, GI, Health information management, Patient, Ambulatory care, Short bowel syndrome, Data analysis, MBA, Internationalized domain name, Dermatology, Nursing

ATLANTA, April 22, 2024 /PRNewswire/ -- OMNY Health is pleased to announce its partnership with the nation's leading community-based independent gastroenterology (GI) practices and integrated delivery networks (IDNs) to launch a novel set of real-world data and evidence solutions for research. Over 5,000 GI providers serving more than 10 million patients are now part of OMNY's research network, representing care delivery by over 380,000 providers and 75 million patients across the US. The focus on GI practice data is a notable expansion to OMNY's real-world data ecosystem, which works with providers to support compliant research partnerships at scale. OMNY works with health systems to enable insights on patient population characteristics, care delivery patterns, and treatment outcomes based on data extracted from de-identified inpatient and ambulatory care electronic health records (EHRs). OMNY's solutions deliver valuable information on disease severity, rationale behind treatment decisions, treatment efficacy, and impact of social determinants on treatment selection and disease progression. By integrating disparate EHRs into unified, de-identified research data products, OMNY offers researchers and providers the breadth and depth of information needed to address their biomedical and population health research questions.

Key Points: 
  • ATLANTA, April 22, 2024 /PRNewswire/ -- OMNY Health is pleased to announce its partnership with the nation's leading community-based independent gastroenterology (GI) practices and integrated delivery networks (IDNs) to launch a novel set of real-world data and evidence solutions for research.
  • "We are thrilled to announce our partnership with OMNY Health, which allows us to drive further insights from our data to advance patient care."
  • Our partnership with OMNY helps ensure our providers have the data and support they need to deliver easy-to-access exceptional GI care."
  • We look forward to building on that impact in the field of gastroenterology," said Mitesh Rao, MD, CEO, OMNY Health.

From Brand Promise to Consumer Voices: 2024 Healthcare Reputation Report Highlights the Power of Feedback in Modern Healthcare Marketing

Retrieved on: 
tisdag, april 16, 2024
Element, Hospital, Health care, Reputation, Human, Patient, Sentiment, Trust, Feedback, Internationalized domain name, Organization, SAN, Pharmaceutical industry

SAN RAMON, Calif., April 16, 2024 /PRNewswire/ -- Reputation, the global leader in reputation performance management, today announced its ranking of the Top 50 U.S. Acute Care Hospitals and Top 20 Hospital Locations in the 2024 Healthcare Reputation Report.

Key Points: 
  • Acute Care Hospitals and Top 20 Hospital Locations in the 2024 Healthcare Reputation Report .
  • To determine these rankings, the report analyzes millions of pieces of reputation performance data from hundreds of different sources, also uncovering insights that highlight how leading U.S.
  • Acute Care Hospitals are delivering on their individual brand promises in a marketplace where the consumer's voice holds more sway than ever before.
  • The 2024 Healthcare Reputation Report found that healthcare marketers are navigating changes in a volatile industry where consumers don't blindly trust brand promises or provider referrals when seeking care.

scPharmaceuticals Inc. Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update

Retrieved on: 
onsdag, mars 13, 2024
Research, Hypersensitivity, Glucose, Deafness, Congestion, Ascites, Furosemide, Cerebral edema, Growth, Edema, Kidney, Ototoxicity, Diuresis, Tinnitus, Bruise, New Drug Application, Patient, Coma, Oliguria, History, NYHA, NDA, Benign prostatic hyperplasia, IDN, Blood volume, Embolism, Insurance, Thrombosis, Trial of the century, Heart failure, Investment, CO2, Urine, Dehydration, Creatinine, Urinary retention, Erythema, Pharmacy, Chronic kidney disease, Organic acid, Patent, Hypoproteinemia, Internationalized domain name, BUN, Huber loss, FDA, Government, GTN, Cirrhosis, Hepatic encephalopathy, Azotemia, Uric acid, Anuria, Pharmaceutical industry

BURLINGTON, Mass., March 13, 2024 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today announced financial results for the fourth quarter and full-year ended December 31, 2023, and provided a business update. 

Key Points: 
  • Product revenues were $6.1 million, and cost of product revenues were $1.8 million for the fourth quarter of 2023.
  • Research and development expenses were $3.3 million for the fourth quarter of 2023, compared to $2.3 million for the fourth quarter of 2022.
  • Selling, general and administrative expenses were $16.2 million for the fourth quarter of 2023, compared to $7.2 million for the fourth quarter of 2022.
  • scPharmaceuticals reported a net loss of $13.8 million for the fourth quarter of 2023, compared to $9.2 million for the fourth quarter of 2022.

Henry Schein Completes Acquisition of Majority Interest of TriMed, Inc.

Retrieved on: 
torsdag, april 4, 2024
Medical Devices, Health, Dental, Physical Therapy, Managed Care, Partnership, Patient, Foot, Sale, Acquisition, Ankle, MD, ASC, Extremities, Internationalized domain name, Wrist, Outpatient surgery

Henry Schein announced the agreement to acquire a majority interest of TriMed on December 20, 2023.

Key Points: 
  • Henry Schein announced the agreement to acquire a majority interest of TriMed on December 20, 2023.
  • The addition of TriMed will strengthen Henry Schein’s deep and longstanding relationship with existing Integrated Delivery Networks (IDNs) and Ambulatory Surgery Center (ASC) customers by providing a wider range of surgical solutions.
  • This reflects the Company’s strategy to expand the sale of Henry Schein-owned brands to new and existing customers.
  • Henry Schein expects the transaction to be neutral to 2024 non-GAAP earnings per share and accretive thereafter.

Olympus Distribution of EndoClot® Showing Steady Adoption in the U.S.

Retrieved on: 
fredag, mars 1, 2024
Static pressure, Traction, Blood, Physician, Tropical ulcer, Dissection, SIS, Polyp, Starch, Hemostasis, Artifact, Internationalized domain name, AMP, Inflammation, Adenoma, Safety, ESD, GI, Water, Classification, Perforated ulcer, CO2, PHS, Patient, Bleeding, Trauma, Perforation, Medical imaging

EndoClot products are used by more than 700 accounts, including most of the country's top-ranked (by size) Integrated Delivery Networks (IDNs).

Key Points: 
  • EndoClot products are used by more than 700 accounts, including most of the country's top-ranked (by size) Integrated Delivery Networks (IDNs).
  • Since their launch, EndoClot products have been discussed in close to 20 relevant professional education courses offered via Olympus Continuum, providing physicians with peer-demonstrations of EndoClot technology capabilities during procedures.
  • "Olympus knew that EndoClot technology would be important to improving procedure efficiencies and contributing to improved patient outcomes," said Patrick Romano, Vice President, GI Business Unit Leader, Olympus Corporation of the Americas.
  • A new video highlighting use of the EndoClot PHS and EndoClot SIS has been developed to provide more information: https://www.youtube.com/watch?v=QlCaoiM2Eo0 .

UA Day 2024: Driving a Multilingual Internet through Universal Acceptance

Retrieved on: 
onsdag, januari 31, 2024
Partnership, LOS, UA Day, Internationalized domain name, Universal Acceptance, TLD, Language, History, Top-level domain, Internet, DNS, Name, RNIDS, ICANN, Culture, Software, Organization

LOS ANGELES, Jan. 31, 2024 /PRNewswire/ -- The Internet Corporation for Assigned Names and Numbers (ICANN) invites the global Internet community to participate in the second annual Universal Acceptance (UA) Day. The keystone UA Day event will be held in Belgrade, Serbia, on 28 March in partnership with the Serbian National Internet Domain Registry Foundation (RNIDS) and the volunteer-based Universal Acceptance Steering Group (UASG). Worldwide supporting events will also be held from March through the end of May.

Key Points: 
  • UA Day Keystone Event to Be Held in Belgrade, Serbia
    LOS ANGELES, Jan. 31, 2024 /PRNewswire/ -- The Internet Corporation for Assigned Names and Numbers (ICANN) invites the global Internet community to participate in the second annual Universal Acceptance (UA) Day.
  • Building on that success, UA Day 2024 will continue to rally local, regional, and global stakeholders to encourage UA adoption.
  • UA Day is a history in the making and hosting the global UA Day event is a privilege indeed," said Dejan Đukić, CEO of RNIDS.
  • "UA Day is a significant opportunity to mobilize the global Internet community and technical stakeholders who can help make UA a reality."

UA Day 2024: Driving a Multilingual Internet through Universal Acceptance

Retrieved on: 
onsdag, januari 31, 2024
Partnership, LOS, UA Day, Internationalized domain name, Universal Acceptance, TLD, Language, History, Top-level domain, Internet, DNS, Name, RNIDS, ICANN, Culture, Software, Organization

LOS ANGELES, Jan. 31, 2024 /PRNewswire/ -- The Internet Corporation for Assigned Names and Numbers (ICANN) invites the global Internet community to participate in the second annual Universal Acceptance (UA) Day. The keystone UA Day event will be held in Belgrade, Serbia, on 28 March in partnership with the Serbian National Internet Domain Registry Foundation (RNIDS) and the volunteer-based Universal Acceptance Steering Group (UASG). Worldwide supporting events will also be held from March through the end of May.

Key Points: 
  • UA Day Keystone Event to Be Held in Belgrade, Serbia
    LOS ANGELES, Jan. 31, 2024 /PRNewswire/ -- The Internet Corporation for Assigned Names and Numbers (ICANN) invites the global Internet community to participate in the second annual Universal Acceptance (UA) Day.
  • Building on that success, UA Day 2024 will continue to rally local, regional, and global stakeholders to encourage UA adoption.
  • UA Day is a history in the making and hosting the global UA Day event is a privilege indeed," said Dejan Đukić, CEO of RNIDS.
  • "UA Day is a significant opportunity to mobilize the global Internet community and technical stakeholders who can help make UA a reality."

R1 RCM Completes Acquisition of Acclara, Providence’s Modular Services Business

Retrieved on: 
onsdag, januari 17, 2024
MSD, BDT, Hand, Centerview Partners, LLP, RCM, Adjustment, Partnership, Kirkland & Ellis, McDermott Will & Emery, Acquisition, J. P. Morgan, Internationalized domain name, Reliability-centered maintenance, Real estate

MURRAY, Utah, Jan. 17, 2024 (GLOBE NEWSWIRE) -- R1 RCM Inc. (NASDAQ: RCM) (“R1”), a leading provider of technology-driven solutions that transform the patient experience and financial performance of healthcare providers, today announced that it has completed its previously announced acquisition of Acclara from Providence, one of the nation's largest health systems. In addition, the Company announced that it expects to release financial results for the fourth quarter and full year ended December 31, 2023, and its 2024 outlook and will host a conference call at 8:00 a.m. ET on Tuesday, February 27, 2024, to discuss the results and business outlook.

Key Points: 
  • ET on Tuesday, February 27, 2024, to discuss the results and business outlook.
  • Upon closing, R1 begins its 10-year partnership with Providence for comprehensive revenue cycle services that leverage the breadth of integrated technology and services capabilities of both R1 and Acclara.
  • Centerview Partners LLC and J.P. Morgan acted as financial advisors to R1, and Perkins Coie LLP, Kirkland & Ellis LLP, and Baker Donelson acted as legal counsel.
  • BDT & MSD Partners acted as financial advisor to Providence, and McDermott Will & Emery and ArentFox Schiff LLP acted as legal counsel.